{'fraction_non_alphanumeric': 0.020172910662824207, 'fraction_numerical': 0.008645533141210375, 'mean_word_length': 4.743801652892562, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
How can we investigate the role of topiramate in the treatment of cocaine use disorder more thoroughly?

We read with interest Darke & Farrell’s [1] commentary on our meta-analysis of topiramate published in the eighth issue of 2016 [2]. To elaborate on some of the ideas raised by the commentary, we focus our response on the question of why some studies implied a benefit and others did not. Overall, although the current evidence is not strong enough to support the routine clinical use of topiramate for the treatment of cocaine use disorder, in certain circumstances it may be useful for researching in terms of helping people with cocaine use disorders to stay abstinent from cocaine use.